Evidence map›Paper›PMID 32016624›Full record

Observational studyJournal of neurology2020

Microbleeds in dementia with Lewy bodies.

Paul C Donaghy, Michael Firbank, Dipayan Mitra, George Petrides, Jim Lloyd, Nicola Barnett, Kirsty Olsen, Alan J Thomas, John T O'Brien

Open access · hybridAbstract readComparative StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 17 citations in OpenAlex.

  1. Plasma Phosphorylated Tau181 as a Biomarker for Alzheimer's Disease Co-Pathology in Lewy Body Disease.Movement disorders : official journal of the Movement Disorder Society · 2025
    Article
  2. Review
  3. Article
  4. Article
  5. Dementia with Lewy bodies: Impact of co-pathologies and implications for clinical trial design.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Paul C DonaghyTranslational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK. paul.donaghy@ncl.ac.uk.ORCID http://orcid.org/0000-0001-7195-4846
Michael FirbankTranslational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
Dipayan MitraNeuroradiology Department, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
George PetridesNuclear Medicine Department, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
Jim LloydNuclear Medicine Department, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
Nicola BarnettTranslational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
Kirsty OlsenTranslational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
Alan J ThomasTranslational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
John T O'BrienDepartment of Psychiatry, University of Cambridge, Cambridge, UK.
Newcastle University · GBNewcastle upon Tyne Hospitals NHS Foundation Trust · GBUniversity of Cambridge · GB

Funding

NIHR Newcastle Biomedical Research Centre BH120812
6 · The paper itself

Abstract

introductionMicrobleeds are associated with the development of dementia in older people and are common in Alzheimer's disease (AD). Their prevalence and clinical importance in dementia with Lewy bodies (DLB) is unclear. The objective of this study was to compare the rates of microbleeds in DLB with those in AD and healthy older people, and investigate associations between microbleeds and amyloid deposition, vascular risk and disease severity in DLB.

methodsDLB (n = 30), AD (n = 18) and control (n = 20) participants underwent clinical assessment at baseline and 1 year in this longitudinal observational study. 3T MRI (including T2* susceptibility weighted imaging) and florbetapir PET were carried out at baseline. Microbleeds were rated visually and a standardised uptake value ratio (SUVR) was calculated from florbetapir PET scans.

results40% of DLB subjects had microbleeds compared with 50% of AD and 15% of controls. Compared to DLB without microbleeds, those with microbleeds had higher systolic BP (156 ± 26 v. 135 ± 19 mmHg; p = 0.03), but did not have greater levels of vascular disease or amyloid deposition (SUVR 1.25 ± 0.24 v. 1.25 ± 0.22; p = 0.33). There was evidence of less severe dementia in DLB participants with microbleeds, but these differences may have been driven by a shorter disease duration in those with microbleeds.

conclusionThe presence of microbleeds in DLB is associated with higher blood pressure, but not with other measures of vascular disease or amyloid deposition. The relationship between microbleeds and clinical presentation remains unclear.

Indexed as

Alzheimer DiseaseCerebral HemorrhageLewy Body DiseaseAgedAged, 80 and overAmyloid beta-PeptidesBlood PressureFemaleHumansLongitudinal StudiesMagnetic Resonance ImagingMalePositron-Emission TomographyAmyloid beta-PeptidesAmyloidDementia with lewy bodiesImagingMicrobleedsVascular

Identifiers

PMID32016624
PMCPMC7184053
OpenAlexW3003407994

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.